Expanded Access Study Amifampridine Phosphate in Congenital Myasthenic Syndrome (CMS)
No longer available
Catalyst Pharmaceuticals, Inc.
1969-12-31
The primary objective of the study is:
• To provide patients with CMSaccess to amifampridine phosphate therapy until the product
becomes commercially available or development is discontinued.
The secondary objective of the study is:
• To assess the long-term safety of amifampridine phosphate in patients with CMS
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
Completed
Catalyst Pharmaceuticals, Inc.
Phase 3
2016-01-01
This randomized, double-blind, controlled, outpatient two-period, two-treatment crossover
study is designed to evaluate the efficacy and safety of amifampridine phosphate in patients
(ages 2 and above) diagnosed with certain genetic subtypes of CMS and demonstrated open label
(amifampridine phosphate) or history of sustained amifampridine benefit from treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
